Unknown

Dataset Information

0

Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.


ABSTRACT: L-dopa-induced dyskinesia (LID) is a common debilitating complication of dopamine replacement therapy in Parkinson's disease. Recent evidence suggests that LID may be linked causally to a hyperactivation of the Ras-ERK signaling cascade in the basal ganglia. We set out to determine whether specific targeting of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a brain-specific activator of the Ras-ERK pathway, may provide a therapy for LID. On the rodent abnormal involuntary movements scale, Ras-GRF1-deficient mice were significantly resistant to the development of dyskinesia during chronic L-dopa treatment. Furthermore, in a nonhuman primate model of LID, lentiviral vectors expressing dominant negative forms of Ras-GRF1 caused a dramatic reversion of dyskinesia severity leaving intact the therapeutic effect of L-dopa. These data reveal the central role of Ras-GRF1 in governing striatal adaptations to dopamine replacement therapy and validate a viable treatment for LID based on intracellular signaling modulation.

SUBMITTER: Fasano S 

PROVIDER: S-EPMC3003069 | biostudies-literature | 2010 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.

Fasano Stefania S   Bezard Erwan E   D'Antoni Angela A   Francardo Veronica V   Indrigo Marzia M   Qin Li L   Doveró Sandra S   Cerovic Milica M   Cenci M Angela MA   Brambilla Riccardo R  

Proceedings of the National Academy of Sciences of the United States of America 20101129 50


L-dopa-induced dyskinesia (LID) is a common debilitating complication of dopamine replacement therapy in Parkinson's disease. Recent evidence suggests that LID may be linked causally to a hyperactivation of the Ras-ERK signaling cascade in the basal ganglia. We set out to determine whether specific targeting of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a brain-specific activator of the Ras-ERK pathway, may provide a therapy for LID. On the rodent abnormal involuntary movements scale,  ...[more]

Similar Datasets

| S-EPMC4479526 | biostudies-literature
| S-EPMC2910545 | biostudies-literature
| S-EPMC3370188 | biostudies-literature
| S-EPMC2654222 | biostudies-literature
| S-EPMC3893648 | biostudies-other
| S-EPMC8318081 | biostudies-literature
| S-EPMC8251786 | biostudies-literature
| S-EPMC3690838 | biostudies-literature
| S-EPMC4900263 | biostudies-literature
| S-EPMC2978093 | biostudies-literature